Abuse of Growth Hormone Among Young Athletes

Pediatric Clinics of North America

Volumn 54, Issue 4, 2007, Pages 823-843

  Buzzini, Sergio R R ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EP 01572; ESTROGEN; IBUTAMOREN; PYRIDOSTIGMINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH HORMONE; SEX HORMONE; SM 130686; UNCLASSIFIED DRUG;

ATHLETE; B LYMPHOCYTE; DRUG ABUSE; DWARFISM; ESTROGEN THERAPY; EXERCISE; FOLLICULAR PHASE; GLYCOLYSIS; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPOCHONDROPLASIA; INTRAUTERINE GROWTH RETARDATION; KIDNEY FAILURE; LUTEAL PHASE; MENSTRUAL CYCLE; PRADER WILLI SYNDROME; PUBERTY; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; TURNER SYNDROME;

ADOLESCENT; DOPING IN SPORTS; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; SPORTS MEDICINE; SUBSTANCE ABUSE DETECTION;

EID: 34548127758     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2007.07.002     Document Type: Review

References (211)

1. Chinese swimmer's bag held banned hormone. New York Times. January 10, 1998. p. C-2.
2. Aussies fine Stallone over growth hormone. The Albuquerque Tribune. May 22, 2007. p. A-6.
3. Campbell D. Growth drug that put out Olympic flame. The Observer. September 10, 2000; section 18-19.
4. Curry J. Pitcher used human growth hormone. New York Times. June 7, 2006. p. D-3.
5. Fainaru-Wada M, Williams L. Sprinter admitted to use of BALCO 'magic potion.' San Francisco Chronicle. June 24, 2004.
6. Fainaru-Wada M, Williams L. Giambi admitted taking steroids. San Francisco Chronicle. December 2, 2004; section A-1.
7. Hall C. Doping for gold. San Francisco Chronicle. September 11, 2000; section A-6.
8. Lemonick M. Le tour des drugs. Time. August 10, 1998. p. 76.
9. Mackay D. How HGH cheats hit the end of the line. The Guardian. July 28, 2004.
10. Reynolds G. Raging hormones. New York Times. August 20, 2006.
11. Samuel A. Tour de France steadfast in ouster of Festina team. New York Times. July 19, 1998. p. A-1.
12. Evans H., and Long J. The effect of the anterior lobe administered intraperitoneally upon growth, maturity, and oestrus cycles of the rat. [abstract]. Anat Rec 21 (1921) 62
13. Engelbach W., Schaeffer R., and Brosius W. Endocrine growth deficiencies: diagnosis and treatment. Endocrinology 17 (1933) 250
14. Li C., and Evans H. Isolation of pituitary growth hormone. Science 99 (1944) 183-184
15. Li C.H., and Papkoff H. Preparation and properties of growth hormone from human and monkey pituitary glands. Science 124 3235 (1956) 1293-1294
16. Raben M.S. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 18 8 (1958) 901-903
17. Underwood L.E., Fisher D.A., Frasier S.D., et al. Degenerative neurologic disease in patients formerly treated with human growth hormone: Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society, May 1985. J Pediatr 107 1 (1985) 10-12
18. Grumbach M.M., Bin-Abbas B.S., and Kaplan S.L. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency. Horm Res 49 Suppl 2 (1998) 41-57
19. Fradkin J.E., Schonberger L.B., Mills J.L., et al. Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 265 7 (1991) 880-884
20. Liu H., Bravata D.M., Olkin I., et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 146 2 (2007) 104-115
21. Saugy M., Robinson N., Saudan C., et al. Human growth hormone doping in sport. Br J Sports Med 40 Suppl 1 (2006) i35-i39
22. Kicman A.T., and Cowan D.A. Peptide hormones and sport: misuse and detection. Br Med Bull 48 3 (1992) 496-517
23. Duchaine D. Underground steroid handbook. 1st edition (1983), HLR Technical Books, Venice (CA)
24. NCAA. NCAA study of substance use habits of college student athletes; 2001. Available at: http://www.ncaa.org/library/research/substance_use_habits/2001/substance_use_habits.pdf. Accessed June 13, 2007.
25. Rickert V.I., Pawlak-Morello C., Sheppard V., et al. Human growth hormone: a new substance of abuse among adolescents?. Clin Pediatr 31 12 (1992) 723-726
26. Hirt H., Kimelman J., Birnbaum M.J., et al. The human growth hormone gene locus: structure, evolution, and allelic variations. DNA 6 1 (1987) 59-70
27. Healy M.L., and Russell-Jones D. Growth hormone and sport: abuse, potential benefits, and difficulties in detection. Br J Sports Med 31 4 (1997) 267-268
28. Frankenne F., Scippo M.L., Van Beeumen J., et al. Identification of placental human growth hormone as the growth hormone-V gene expression product. J Clin Endocrinol Metab 71 1 (1990) 15-18
29. Eriksson L., Frankenne F., Eden S., et al. Growth hormone 24-h serum profiles during pregnancy-lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 96 8 (1989) 949-953
30. de Zegher F., Vanderschueren-Lodeweyckx M., Spitz B., et al. Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH. J Clin Endocrinol Metab 71 2 (1990) 520-522
31. Liu N., Mertani H.C., Norstedt G., et al. Mode of the autocrine/paracrine mechanism of growth hormone action. Exp Cell Res 237 1 (1997) 196-206
32. Harvey S., and Hull K.L. Growth hormone. A paracrine growth factor?. Endocrine 7 3 (1997) 267-279
33. Boguszewski C.L. Molecular heterogeneity of human GH: from basic research to clinical implications. J Endocrinol Invest 26 3 (2003) 274-288
34. Baumann G. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 51 Suppl 1 (1999) 2-6
35. Lewis U.J., Sinha Y.N., and Lewis G.P. Structure and properties of members of the hGH family: a review. Endocr J 47 Suppl (2000) S1-S8
36. Bidlingmaier M., Wu Z., and Strasburger C.J. Test method: GH. Baillieres Best Pract Res 14 1 (2000) 99-109
37. Baumann G. Growth hormone binding proteins and various forms of growth hormone: implications for measurements. Acta Paediatr Scand 370 (1990) 72-80 [discussion: 1]
38. Muller E.E., Locatelli V., and Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev 79 2 (1999) 511-607
39. Kojima M., Hosoda H., Date Y., et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 6762 (1999) 656-660
40. Tannenbaum G.S., Epelbaum J., and Bowers C.Y. Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144 3 (2003) 967-974
41. Molitch M.E., Clemmons D.R., Malozowski S., et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91 5 (2006) 1621-1634
42. Ho K.Y., Evans W.S., Blizzard R.M., et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64 1 (1987) 51-58
43. Albertsson-Wikland K., Rosberg S., Karlberg J., et al. Analysis of 24-hour growth hormone profiles in healthy boys and girls of normal stature: relation to puberty. J Clin Endocrinol Metab 78 5 (1994) 1195-1201
44. Stolar M.W., and Baumann G. Secretory patterns of growth hormone during basal periods in man. Metabolism 35 9 (1986) 883-888
45. Cappellin E., Gatti R., and De Palo E.F. Influence of gender in growth hormone status in adults: role of urinary growth hormone. Clin Chem 45 3 (1999) 443-444
46. Rogol A.D., Martha P., Johnson M., et al. Growth hormone secretory dynamics during puberty. In: Adashi E., and Thorner M. (Eds). The somatotrophic axis and the reproductive process in health and disease (1995), Springer-Verlag, New York
47. Iranmanesh A., Lizarralde G., and Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73 5 (1991) 1081-1088
48. Sonksen P.H., and Christiansen J.S. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Growth Hormone Research Society. Growth Horm IGF Res 8 Suppl B (1998) 89-92
49. Herington A.C., Ymer S., and Stevenson J. Identification and characterization of specific binding proteins for growth hormone in normal human sera. J Clin Invest 77 6 (1986) 1817-1823
50. Baumann G., Stolar M.W., Amburn K., et al. A specific growth hormone-binding protein in human plasma: initial characterization. J Clin Endocrinol Metab 62 1 (1986) 134-141
51. Leung D.W., Spencer S.A., Cachianes G., et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 330 6148 (1987) 537-543
52. Leung K.C., Doyle N., Ballesteros M., et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A 100 3 (2003) 1016-1021
53. Mullis P.E., Wagner J.K., Eble A., et al. Regulation of human growth hormone receptor gene transcription by human growth hormone binding protein. Mol Cell Endocrinol 131 1 (1997) 89-96
54. Brown R.J., Adams J.J., Pelekanos R.A., et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12 9 (2005) 814-821
55. Chen C., Brinkworth R., and Waters M.J. The role of receptor dimerization domain residues in growth hormone signaling. J Biol Chem 272 8 (1997) 5133-5140
56. Pearce Jr. K.H., Ultsch M.H., Kelley R.F., et al. Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface. Biochemistry 35 32 (1996) 10300-10307
57. Goffin V., Shiverick K.T., Kelly P.A., et al. Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. Endocr Rev 17 4 (1996) 385-410
58. Fuh G., Cunningham B.C., Fukunaga R., et al. Rational design of potent antagonists to the human growth hormone receptor. Science 256 5064 (1992) 1677-1680
59. Rigamonti A.E., Cella S.G., Marazzi N., et al. Growth hormone abuse: methods of detection. Trends Endocrinol Metab 16 4 (2005) 160-166
60. Martin J.L., Coverley J.A., Pattison S.T., et al. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136 3 (1995) 1219-1226
61. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336 9 (1997) 633-640
62. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 3 (2006) 1500-1508
63. Fryburg D.A., Jahn L.A., Hill S.A., et al. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 96 4 (1995) 1722-1729
64. Butler A.A., and Le Roith D. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 63 (2001) 141-164
65. Le Roith D., Scavo L., and Butler A. What is the role of circulating IGF-I?. Trends Endocrinol Metab 12 2 (2001) 48-52
66. Clemmons D.R. Quantitative measurement of IGF-I and its use in diagnosing and monitoring treatment of disorders of growth hormone secretion. Endocr Dev 9 (2005) 55-65
67. Butterfield G.E., Thompson J., Rennie M.J., et al. Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am J Physiol 272 1 Pt 1 (1997) E94-E99
68. Brabant G., von zur Muhlen A., Wuster C., et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 60 2 (2003) 53-60
69. Milani D., Carmichael J.D., Welkowitz J., et al. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89 5 (2004) 2271-2274
70. Parker M.L., Utiger R.D., and Daughaday W.H. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J Clin Invest 41 (1962) 262-268
71. Baumann G. Growth hormone binding protein 2001. J Pediatr Endocrinol Metab 14 4 (2001) 355-375
72. Ho K.Y., Weissberger A.J., Stuart M.C., et al. The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. Clin Endocrinol (Oxf) 30 4 (1989) 335-345
73. van den Berg G., Veldhuis J.D., Frolich M., et al. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81 7 (1996) 2460-2467
74. Peacey S.R., Toogood A.A., Veldhuis J.D., et al. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86 1 (2001) 259-266
75. Krogsgaard Thomsen M., Friis C., Sehested Hansen B., et al. Studies on the renal kinetics of growth hormone (GH) and on the GH receptor and related effects in animals. J Pediatr Endocrinol 7 2 (1994) 93-105
76. de Boer H., Blok G.J., and Van der Veen E.A. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16 1 (1995) 63-86
77. Tanner J.W., Leingang K.A., Mueckler M.M., et al. Cellular mechanism of the insulin-like effect of growth hormone in adipocytes. Rapid translocation of the HepG2-type and adipocyte/muscle glucose transporters. Biochem J 282 Pt 1 (1992) 99-106
78. Fowelin J., Attvall S., von Schenck H., et al. Characterization of the insulin-antagonistic effect of growth hormone in man. Diabetologia 34 7 (1991) 500-506
79. Lissett C.A., and Shalet S.M. Effects of growth hormone on bone and muscle. Growth Horm IGF Res 10 Suppl B (2000) S95-S101
80. Nussey S., and Whitehead S. Endocrinology: an integrated approach (2001), BIOS Scientific Publishers Limited, London
81. Vance M.L., and Mauras N. Growth hormone therapy in adults and children. N Engl J Med 341 16 (1999) 1206-1216
82. Carroll P.V., Christ E.R., Bengtsson B.A., et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83 2 (1998) 382-395
83. Auernhammer C.J., and Strasburger C.J. Effects of growth hormone and insulin-like growth factor I on the immune system. Eur J Endocrinol 133 6 (1995) 635-645
84. Samra J.S., Clark M.L., Humphreys S.M., et al. Suppression of the nocturnal rise in growth hormone reduces subsequent lipolysis in subcutaneous adipose tissue. Eur J Clin Invest 29 12 (1999) 1045-1052
85. Sonksen P.H. Insulin, growth hormone and sport. J Endocrinol 170 1 (2001) 13-25
86. Ohlsson C., Bengtsson B.A., Isaksson O.G., et al. Growth hormone and bone. Endocr Rev 19 1 (1998) 55-79
87. Melmed S. Acromegaly. N Engl J Med 322 14 (1990) 966-977
88. American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. Considerations related to the use of recombinant human growth hormone in children. Pediatrics 99 1 (1997) 122-129
89. Badia X., Lucas A., Sanmarti A., et al. One-year follow-up of quality of life in adults with untreated growth hormone deficiency. Clin Endocrinol (Oxf) 49 6 (1998) 765-771
90. Dean H.J., McTaggart T.L., Fish D.G., et al. The educational, vocational, and marital status of growth hormone-deficient adults treated with growth hormone during childhood. Am J Dis Child 139 11 (1985) 1105-1110
91. Baum H.B., Biller B.M., Finkelstein J.S., et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125 11 (1996) 883-890
92. Biller B.M., Sesmilo G., Baum H.B., et al. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 85 3 (2000) 970-976
93. Feldt-Rasmussen U., Wilton P., and Jonsson P. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Horm IGF Res 14 Suppl A (2004) S51-S58
94. Monson J.P. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 148 Suppl 2 (2003) S9-S14
95. Flanagan D.E., Taylor M.C., Parfitt V., et al. Urinary growth hormone following exercise to assess growth hormone production in adults. Clin Endocrinol (Oxf) 46 4 (1997) 425-429
96. Galbo H. The hormonal response to exercise. Proc Nutr Soc 44 2 (1985) 257-266
97. Kraemer R.R., Blair M.S., McCaferty R., et al. Running-induced alterations in growth hormone, prolactin, triiodothyronine, and thyroxine concentrations in trained and untrained men and women. Res Q Exerc Sport 64 1 (1993) 69-74
98. Snegovskaya V., and Viru A. Steroid and pituitary hormone responses to rowing: relative significance of exercise intensity and duration and performance level. Eur J Appl Physiol Occup Physiol 67 1 (1993) 59-65
99. Snegovskaya V., and Viru A. Elevation of cortisol and growth hormone levels in the course of further improvement of performance capacity in trained rowers. Int J Sports Med 14 4 (1993) 202-206
100. Weltman J.Y., Weltman A.F., van der Heijden M., et al. Effect of intensity of exercise on 24-hour growth hormone (GH) release. Med Sci Sports Exerc 26 Suppl 5 (1994) S37
101. Bunt J.C., Boileau R.A., Bahr J.M., et al. Sex and training differences in human growth hormone levels during prolonged exercise. J Appl Physiol 61 5 (1986) 1796-1801
102. Wideman L., Weltman J.Y., Shah N., et al. Effects of gender on exercise-induced growth hormone release. J Appl Physiol 87 3 (1999) 1154-1162
103. Marin G., Domene H.M., Barnes K.M., et al. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 79 2 (1994) 537-541
104. Kraemer R.R., Heleniak R.J., Tryniecki J.L., et al. Follicular and luteal phase hormonal responses to low-volume resistive exercise. Med Sci Sports Exerc 27 6 (1995) 809-817
105. Gordon S.E., Kraemer W.J., Vos N.H., et al. Effect of acid-base balance on the growth hormone response to acute high-intensity cycle exercise. J Appl Physiol 76 2 (1994) 821-829
106. Thompson D.L., Weltman J.Y., Rogol A.D., et al. Cholinergic and opioid involvement in release of growth hormone during exercise and recovery. J Appl Physiol 75 2 (1993) 870-878
107. Cappa M., Grossi A., Benedetti S., et al. Effect of the enhancement of the cholinergic tone by pyridostigmine on the exercise-induced growth hormone release in man. J Endocrinol Invest 16 6 (1993) 421-424
108. Brillon D., Nabil N., and Jacobs L.S. Cholinergic but not serotonergic mediation of exercise-induced growth hormone secretion. Endocr Res 12 2 (1986) 137-146
109. Galbo H., Holst J.J., and Christensen N.J. The effect of different diets and of insulin on the hormonal response to prolonged exercise. Acta Physiol Scand 107 1 (1979) 19-32
110. Johannessen A., Hagen C., and Galbo H. Prolactin, growth hormone, thyrotropin, 3,5,3′-triiodothyronine, and thyroxine responses to exercise after fat- and carbohydrate-enriched diet. J Clin Endocrinol Metab 52 1 (1981) 56-61
111. Nieman D.C., Nehlsen-Cannarella S.L., Fagoaga O.R., et al. Influence of mode and carbohydrate on the cytokine response to heavy exertion. Med Sci Sports Exerc 30 5 (1998) 671-678
112. Tsintzas O.K., Williams C., Wilson W., et al. Influence of carbohydrate supplementation early in exercise on endurance running capacity. Med Sci Sports Exerc 28 11 (1996) 1373-1379
113. Jenkins P.J. Growth hormone and exercise. Clin Endocrinol (Oxf) 50 6 (1999) 683-689
114. Bang P., Brandt J., Degerblad M., et al. Exercise-induced changes in insulin-like growth factors and their low molecular weight binding protein in healthy subjects and patients with growth hormone deficiency. Eur J Clin Invest 20 3 (1990) 285-292
115. Cappon J., Brasel J.A., Mohan S., et al. Effect of brief exercise on circulating insulin-like growth factor I. J Appl Physiol 76 6 (1994) 2490-2496
116. Deyssig R., and Frisch H. Self-administration of cadaveric growth hormone in power athletes. Lancet 341 8847 (1993) 768-769
117. Kraemer W.J., Fleck S.J., Dziados J.E., et al. Changes in hormonal concentrations after different heavy-resistance exercise protocols in women. J Appl Physiol 75 2 (1993) 594-604
118. Kraemer W.J., Marchitelli L., Gordon S.E., et al. Hormonal and growth factor responses to heavy resistance exercise protocols. J Appl Physiol 69 4 (1990) 1442-1450
119. Schwarz A.J., Brasel J.A., Hintz R.L., et al. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab 81 10 (1996) 3492-3497
120. Di Luigi L., Conti F.G., Casini A., et al. Growth hormone and insulin-like growth factor I responses to moderate submaximal acute physical exercise in man: effects of octreotide, a somatostatin analogue, administration. Int J Sports Med 18 4 (1997) 257-263
121. Hellenius M.L., Brismar K.E., Berglund B.H., et al. Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. J Intern Med 238 2 (1995) 121-130
122. Hopkins N.J., Jakeman P.M., Hughes S.C., et al. Changes in circulating insulin-like growth factor-binding protein-1 (IGFBP-1) during prolonged exercise: effect of carbohydrate feeding. J Clin Endocrinol Metab 79 6 (1994) 1887-1890
123. Jahreis G., Hesse V., Schmidt H.E., et al. Effect of endurance exercise on somatomedin-C/insulin-like growth factor I concentration in male and female runners. Exp Clin Endocrinol 94 1-2 (1989) 89-96
124. Kraemer W.J., Aguilera B.A., Terada M., et al. Responses of IGF-I to endogenous increases in growth hormone after heavy-resistance exercise. J Appl Physiol 79 4 (1995) 1310-1315
125. Sartorio A., Marazzi N., Agosti F., et al. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers: a study on-the-field. J Endocrinol Invest 27 5 (2004) 410-415
126. Eliakim A., Brasel J.A., Barstow T.J., et al. Peak oxygen uptake, muscle volume, and the growth hormone-insulin-like growth factor-I axis in adolescent males. Med Sci Sports Exerc 30 4 (1998) 512-517
127. Eliakim A., Brasel J.A., Mohan S., et al. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J Clin Endocrinol Metab 81 11 (1996) 3986-3992
128. Cappa M, Ubertini G, Colabianchi D, et-al. Non-conventional use of growth hormone therapy. Acta Paediatr Suppl;95(452):9-13.
129. Gibney J., Wallace J.D., Spinks T., et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84 8 (1999) 2596-2602
130. Jorgensen J.O., Thuesen L., Muller J., et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 130 3 (1994) 224-228
131. Jorgensen J.O., Vahl N., Hansen T.B., et al. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol (Oxf) 45 6 (1996) 681-688
132. Salomon F., Cuneo R.C., Hesp R., et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321 26 (1989) 1797-1803
133. Barkan A.L., Clemmons D.R., Molitch M.E., et al. Growth hormone therapy for hypopituitary adults: time for re-appraisal. Trends Endocrinol Metab 11 6 (2000) 238-245
134. Merola B., Longobardi S., Sofia M., et al. Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months' growth hormone replacement therapy. Eur J Endocrinol 135 5 (1996) 553-558
135. Christ E.R., Cummings M.H., Westwood N.B., et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 82 9 (1997) 2985-2990
136. Ten Have S.M., van der Lely A.J., and Lamberts S.W. Increase in haemoglobin concentrations in growth hormone deficient adults during human recombinant growth hormone replacement therapy. Clin Endocrinol (Oxf) 47 5 (1997) 565-570
137. Cuneo R.C., Salomon F., Wiles C.M., et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol 70 2 (1991) 695-700
138. Cuneo R.C., Salomon F., Wiles C.M., et al. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 70 2 (1991) 688-694
139. Beshyah S.A., Freemantle C., Shahi M., et al. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 42 1 (1995) 73-84
140. Jorgensen J.O., Pedersen S.A., Thuesen L., et al. Long-term growth hormone treatment in growth hormone deficient adults. Acta Endocrinol (Copenh) 125 5 (1991) 449-453
141. Rodriguez-Arnao J., Jabbar A., Fulcher K., et al. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults. Clin Endocrinol (Oxf) 51 1 (1999) 53-60
142. Cittadini A., Cuocolo A., Merola B., et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 267 2 Pt 1 (1994) E219-E225
143. Cuneo R.C., Salomon F., Wilmshurst P., et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Lond) 81 5 (1991) 587-592
144. Radcliffe D.J., Pliskin J.S., Silvers J.B., et al. Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 22 8 (2004) 499-524
145. Bryant J., Cave C., Mihaylova B., et al. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technol Assess 6 18 (2002) 1-168
146. Gharib H., Cook D.M., Saenger P.H., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract 9 1 (2003) 64-76
147. Hoffman A.R., Strasburger C.J., Zagar A., et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89 7 (2004) 3224-3233
148. Johannsson G., Rosen T., and Bengtsson B.A. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 47 5 (1997) 571-581
149. Burman P., Johansson A.G., Siegbahn A., et al. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82 2 (1997) 550-555
150. Drake W.M., Coyte D., Camacho-Hubner C., et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 83 11 (1998) 3913-3919
151. Cook D.M., Ludlam W.H., and Cook M.B. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 84 11 (1999) 3956-3960
152. Underwood L.E., Attie K.M., and Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88 11 (2003) 5273-5280
153. GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. J Clin Endocrinol Metab 85 11 (2000) 3990-3993
154. Lee J.M., Davis M.M., Clark S.J., et al. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med 160 3 (2006) 263-269
155. Wilson T.A., Rose S.R., Cohen P., et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J Pediatr 143 4 (2003) 415-421
156. Bengtsson B.A., Eden S., Lonn L., et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76 2 (1993) 309-317
157. Rosen T., Johannsson G., and Bengtsson B.A. Consequences of growth hormone deficiency in adults, and effects of growth hormone replacement therapy. Acta Paediatr Suppl 399 (1994) 21-24 [discussion: 5]
158. Drake W.M., Carroll P.V., Maher K.T., et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 88 4 (2003) 1658-1663
159. Allen D.B., and Fost N. hGH for short stature: ethical issues raised by expanded access. J Pediatr 144 5 (2004) 648-652
160. Cuttler L., and Silvers J.B. Growth hormone treatment for idiopathic short stature: implications for practice and policy. Arch Pediatr Adolesc Med 158 2 (2004) 108-110
161. Growth hormone for normal short children. Med Lett Drugs Ther 45 1169 (2003) 89-90
162. Jenkins P.J. Growth hormone and exercise: physiology, use and abuse. Growth Horm IGF Res 11 Suppl A (2001) S71-S77
163. van der Lely A.J. Hormone use and abuse: what is the difference between hormones as fountain of youth and doping in sports?. J Endocrinol Invest 26 9 (2003) 932-936
164. Rennie M.J. Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes?. Br J Sports Med 37 2 (2003) 100-105
165. Crist D.M., Peake G.T., Egan P.A., et al. Body composition response to exogenous GH during training in highly conditioned adults. J Appl Physiol 65 2 (1988) 579-584
166. Deyssig R., Frisch H., Blum W.F., et al. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh) 128 4 (1993) 313-318
167. Karila T., Koistinen H., Seppala M., et al. Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes. Clin Endocrinol (Oxf) 49 4 (1998) 459-463
168. Pierard-Franchimont C., Henry F., Crielaard J.M., et al. Mechanical properties of skin in recombinant human growth factor abusers among adult bodybuilders. Dermatology 192 4 (1996) 389-392
169. Taaffe D.R., Jin I.H., Vu T.H., et al. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 81 1 (1996) 421-425
170. Yarasheski K.E., Campbell J.A., Smith K., et al. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 262 3 Pt 1 (1992) E261-E267
171. Yarasheski K.E., Zachweija J.J., Angelopoulos T.J., et al. Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J Appl Physiol 74 6 (1993) 3073-3076
172. Koch J.J. Performance-enhancing: substances and their use among adolescent athletes. Pediatr Rev 23 9 (2002) 310-317
173. Schnirring L. Growth hormone doping: the search for a test. Phys Sportsmed 28 4 (2000) 16-18
174. Lange K.H., Larsson B., Flyvbjerg A., et al. Acute growth hormone administration causes exaggerated increases in plasma lactate and glycerol during moderate to high intensity bicycling in trained young men. J Clin Endocrinol Metab 87 11 (2002) 4966-4975
175. Cittadini A., Berggren A., Longobardi S., et al. Supraphysiological doses of GH induce rapid changes in cardiac morphology and function. J Clin Endocrinol Metab 87 4 (2002) 1654-1659
176. Jenkins P.J., Fairclough P.D., Richards T., et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 47 1 (1997) 17-22
177. Mastaglia F.L., Barwich D.D., and Hall R. Myopathy in acromegaly. Lancet 2 7679 (1970) 907-909
178. Melmed S. Medical progress: acromegaly. N Engl J Med 355 24 (2006) 2558-2573
179. Nabarro J.D. Acromegaly. Clin Endocrinol (Oxf) 26 4 (1987) 481-512
180. Orme S.M., McNally R.J., Cartwright R.A., et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 8 (1998) 2730-2734
181. Allen N.E., Roddam A.W., Allen D.S., et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 92 7 (2005) 1283-1287
182. Biermasz N.R., Pereira A.M., Smit J.W., et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90 5 (2005) 2731-2739
183. Clayton P.E., and Cowell C.T. Safety issues in children and adolescents during growth hormone therapy-a review. Growth Horm IGF Res 10 6 (2000) 306-317
184. Clayton R.N. Cardiovascular function in acromegaly. Endocr Rev 24 3 (2003) 272-277
185. Colao A., Ferone D., Marzullo P., et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25 1 (2004) 102-152
186. Malozowski S., and Stadel B.V. Prepubertal gynecomastia during growth hormone therapy. J Pediatr 126 4 (1995) 659-661
187. Okasha M., Gunnell D., Holly J., et al. Childhood growth and adult cancer. Best Pract Res Clin Endocrinol Metab 16 2 (2002) 225-241
188. Perry J.K., Emerald B.S., Mertani H.C., et al. The oncogenic potential of growth hormone. Growth Horm IGF Res 16 5-6 (2006) 277-289
189. Renehan A.G., and Shalet S.M. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 87 4 (2002) 1909; author reply
190. Seminara S., Merello G., Masi S., et al. Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clin Endocrinol (Oxf) 49 1 (1998) 125-130
191. Swerdlow A.J., Higgins C.D., Adlard P., et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 360 9329 (2002) 273-277
192. Takala J., Ruokonen E., Webster N.R., et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341 11 (1999) 785-792
193. Wu Z., Bidlingmaier M., Dall R., et al. Detection of doping with human growth hormone. Lancet 353 9156 (1999) 895
194. Bidlingmaier M., Wu Z., and Strasburger C.J. Problems with GH doping in sports. J Endocrinol Invest 26 9 (2003) 924-931
195. Wallace J.D., Cuneo R.C., Baxter R., et al. Detection of growth hormone abuse in athletes. Growth Horm IGF Res 8 4 (1998) 347-348
196. Wallace J.D., Cuneo R.C., Rosen T., et al. Bone markers and growth hormone (GH) abuse in athletes. Growth Horm IGF Res 8 4 (1998) 348
197. Longobardi S., Keay N., Ehrnborg C., et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J Clin Endocrinol Metab 85 4 (2000) 1505-1512
198. Wallace J.D., Cuneo R.C., Lundberg P.A., et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 85 1 (2000) 124-133
199. Legovini P., De Menis E., Breda F., et al. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. J Endocrinol Invest 20 8 (1997) 434-438
200. Piovesan A., Terzolo M., Reimondo G., et al. Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Horm Metab Res 26 5 (1994) 234-237
201. Ehrnborg C., Lange K.H., Dall R., et al. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test. J Clin Endocrinol Metab 88 1 (2003) 394-401
202. Holl R.W., Schwarz U., Schauwecker P., et al. Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J Clin Endocrinol Metab 77 1 (1993) 216-220
203. Saugy M., Cardis C., Schweizer C., et al. Detection of human growth hormone doping in urine: out of competition tests are necessary. J Chromatogr 687 1 (1996) 201-211
204. Backeljauw P.F., and Underwood L.E. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome-a clinical research center study. GHIS Collaborative Group. J Clin Endocrinol Metab 81 9 (1996) 3312-3317
205. Isidro M.L., and Cordido F. Growth hormone secretagogues. Comb Chem High Throughput Screen 9 3 (2006) 175-180
206. Kanayama G., Pope H.G., Cohane G., et al. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend 71 1 (2003) 77-86
207. Calfee R., and Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics 117 3 (2006) e577-e589
208. National Federation of State High School Associations. Sports medicine: high school drug-testing programs: August 2003. Available at: www.nfhs.org. Accessed June 13, 2007.
209. Goldberg L., Elliot D., Clarke G.N., et al. Effects of a multidimensional anabolic steroid prevention intervention. The Adolescents Training and Learning to Avoid Steroids (ATLAS) Program. JAMA 276 19 (1996) 1555-1562
210. Goldberg L., MacKinnon D.P., Elliot D.L., et al. The adolescents training and learning to avoid steroids program: preventing drug use and promoting health behaviors. Arch Pediatr Adolesc Med 154 4 (2000) 332-338
211. Elliot D.L., Goldberg L., Moe E.L., et al. Preventing substance use and disordered eating: initial outcomes of the ATHENA (athletes targeting healthy exercise and nutrition alternatives) program. Arch Pediatr Adolesc Med 158 11 (2004) 1043-1049